Skip to Main content Skip to Navigation
Journal articles

Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.

Abstract : Everolimus (rapamycin derivative, RAD) is a new immunosuppressive drug that prevents allograft rejection. Herein, the pharmacodynamics of everolimus in human renal-allograft recipients is evaluated. Single doses of everolimus (0.75-10mg), combined with a maintenance immunosuppressive therapy based on CyA, decreased lymphocyte proliferation. In addition, the effect of multiple doses of everolimus (0.75-10mg) given daily for 21 days, to stable renal-allograft patients (n=11), was investigated. Everolimus treatment resulted in immediate inhibition (25-55%) of lymphocyte proliferation in renal-allograft recipients; values returning to baseline by 14 days after cessation of everolimus treatment. Placebo-treated patients showed no decrease in lymphocyte proliferation. Interestingly, everolimus reduced IL-10 synthesis by 20-60% in renal-allograft recipients. Phagocytosis rates were not changed by everolimus. In vitro, everolimus inhibited lymphocyte proliferation and IL-10 synthesis dose dependently in anti-CD3 mAb and LPS stimulated peripheral blood mononuclear cell cultures derived from human volunteers.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00408849
Contributor : Marie Francoise Simon <>
Submitted on : Monday, August 3, 2009 - 4:57:48 PM
Last modification on : Friday, January 10, 2020 - 9:09:08 PM

Identifiers

Collections

Citation

Torsten Böhler, Johannes Waiser, Steffi Lichter, Brit Schumann, Hans-H Neumayer, et al.. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.. Cytokine / Cytokines, 2008, 42 (3), pp.306-11. ⟨10.1016/j.cyto.2008.02.015⟩. ⟨inserm-00408849⟩

Share

Metrics

Record views

277